Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Íåâðîëîãèÿ è íåéðîõèðóðãèÿ

Íåâðîëîãèÿ è íåéðîõèðóðãèÿ Ôîðóìû: Ôîðóì äëÿ îáùåíèÿ âðà÷åé íåâðîëîãîâ è íåéðîõèðóðãîâ, Ìàíóàëüíàÿ òåðàïèÿ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 14.05.2003, 13:45
Elena Elephant Elena Elephant âíå ôîðóìà
Ñåðôåð
 
Ðåãèñòðàöèÿ: 14.05.2003
Ãîðîä: Moscow
Ñîîáùåíèé: 6
Elena Elephant *
Ãîëîâíàÿ áîëü, ìèãðåíü

Äîáðûé äåíü!
Ìåíÿ çîâóò Åëåíà, ìíå 30 ëåò.
Õî÷ó óçíàòü ÷òî-íèáóäü ïî ïðîáëåìå ìèãðåíè.
Î÷åíü ìó÷àþò ãîëîâíûå áîëè, äàâíî (ñ äåòñòâà), îòåö ñòðàäàåò òåì æå (ãîâîðÿò, òàêàÿ áîëåçíü ïåðåäàåòñÿ îò ðîäèòåëÿ ê ðåáåíêó ñ äðóíèì ïîëîì, òî åñòü îòåö-äî÷ü).
Ñèòóàöèÿ óõóäøàåòñÿ ñ êàæäûì ãîäîì. Ïðèñòóïû ãîëîâíîé áîëè î÷åíü ÷àñòûå è äëèòåëüíûå (áûâàåò äî äâóõ íåäåëü ïîäðÿä). Ïðè ýòîì ñëåäóþùèå ñèìïòîìû:
- ãîëîâíàÿ áîëü â îäíîé òî÷êå, â âèñêàõ, â çàòûëêå è ò.ï.
- áîëü è ðåçü â ãëàçàõ, áîëü â ãëàçíèöàõ, áîëü â ëèöå (íàäáðîâíûå äóãè, íîñ, ïîä ëèöåâûìè êîñòÿìè), èíîãäà áîëü çà óøàìè
-èíîãäà òîøíîòà, íåïåðåíîñèìîñòü çàïàõîâ è ñâåòà
-áîëü â øåéíûõ ïîçâîíêàõ, íåïðèÿòíûå äèñêîìôîðòíûå îùóùåíèÿ â øåå ñçàäè, èíîãäà áîëü â ïîçâîíî÷íèêå
-áîëü ïóëüñèðóþùàÿ, óñèëèâàåòñÿ ïðè íàêëîíå

Ïðîáîâàëà ëå÷èòüñÿ ìàññàæàìè (îñòèîõîíäðîç), èãëîóêàëûâàíèåì. Íå ïîìîãëî... Äàæå øóì â óøàõ ïîÿâèëñÿ ïîñëå ñåàíñîâ. Ïðîøëà îáñëåäîâàíèå ó íåâðîïàòîëîãà è îôòàëüìîëîãà. Íè÷åãî ñòðàøíîãî íå îáíàðóæèëîñü.
Ïðèíèìàþ òàáëåòêè (òîëüêî, êîãäà áîëèò ãîëîâà) - áàðàëãèí, íîøïà, ïàïàçîë, àíäèïàë, êåòàíîâ è ïðî÷åå. Ìíîãè ñðåäñòâà óæå íå ïîìîãàþò. Ïîêà ïîìîãàåò êîìïðåñ (õîëîäíûé íà ëîá, ãîðÿ÷èé íà çàòûëîê), ïîëíûé ïîêîé è ñîí (åñëè óäàåòñÿ ñðàçó çàñíóòü - ýòî ñ÷àñòüå!).
Âîïðîñ: ïîñîâåòóéòå, ìîæíî ëè ïîëíîñòüþ èçëå÷èòüñÿ îò ìèãðåíè (ìíîãèå ãîâîðÿò, ÷òî òàêîå íå ëå÷èòñÿ è âîîáùå áîëåçíü íåèçâåñòíîãî ïðîèñõîæäåíèÿ), êàêèå ëåêàðñòâà ëó÷øå ïðèíèìàòü îò áîëåé. Ìîæíî ëè ñîáëþäàòü äèåòó è ïîìî÷ü ñåáå? ×òî íåëüçÿ äåëàòü ïðè òàêîì çàáîëåâàíèè (ÿ êóðþ è çàíèìàþñü ñïîðòîì)? Êàê ìîæíî ñíèçèòü èíòåíñèâíîñòü áîëåé è èõ ïðîäîëæèòåëüíîñòü (íåäàâíî ïîñ÷èòàëà, ïîëó÷èëîñü ÷òî ó ìåíÿ áîëèò ãîëîâà (ïðè÷åì æóòêî) 5-10 äíåé â ìåñÿö.
Çàðàíåå áëàãîäàðþ.
Ñ óâàæåíèåì.
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 20.05.2003, 12:13
Elena Elephant Elena Elephant âíå ôîðóìà
Ñåðôåð
 
Ðåãèñòðàöèÿ: 14.05.2003
Ãîðîä: Moscow
Ñîîáùåíèé: 6
Elena Elephant *
Ìèãðåíü

ß íå ïîëó÷èëà íèêàêîãî îòâåòà íà ìîå ïîñëàíèå. Ïîæàëóéñòà, ñîîáùèòå, ïî âîçìîæíîñòè, êðàòêèé îòâåò. Ìîæåò áûòü, ÿ îáðàòèëàñü íå ïî àäðåñó???
Ñïàñèáî.
Åëåíà
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 20.05.2003, 15:44
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,505
Ïîáëàãîäàðèëè 33,289 ðàç(à) çà 31,637 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâ. Åëåíà!
Ïîñòàðàéòåñü èçáåãàòü òåõ íåïðèÿòíûõ ìîìåíòîâ, êîòîðûå âûçûâàþò ó âàñ ïðèñòóïû (íàïð. ñòðåññ, ãîëîä, íåâûñûïàíèå). Äëÿ êóïèðîâàíèÿ ïðèñòóïîâ ìîæíî èñïîëüçîâàòü ñóìàòðèïòàí (íàâåðíîå ëó÷øå â âèäå èíòðàíàçàëüíûõ ñïðååâ), òàêæå ìîæåò ïîäîéòè ïðåïàðàòû èç ãðóïïû íåñòåðîèäíûõ ïðîòèâîâîñïàëèòåëüíûõ (íàïð. êåòîïðîôåí 75 èëè 150 ìã â äåíü èëè æå íàïðîêñåí, äèêëîôåíàê), ñî÷åòàíèå 900 ìã àñïèðèíà ñ 10 ìã ìåòîêëîïðàìèäà. Ñî÷åòàííîå ïðèìåíåíèå ñóìàòðèïòàíà è íàïðîêñåíà ìîæåò óìåíüøèòü êîëè÷åñòâî ïîâòîðíûõ ïðèñòóïîâ. Äëÿ ïðîôèëàêòèêè ìîæíî ïîïðîáîâàòü 40 ìã òðèæäû â äåíü âåðàïàìèëà (åñëè íåò êîíå÷íî ñêëîííîñòè ê ðåäêîìó ïóëüñó èëè ñåðä. ïàòîëîãèè). Åñëè êóðåíèå èëè ôèçíàãðóçêè ñàìè ïî ñåáå íå áûëè çàìå÷åíû â èíèöèàöèè ïðèñòóïîâ, òî ìîæíî ïðîäîëæàòü â òîì æå äóõå (ïîïðîáóéòå äîâåñòè åæåäíåâíûé ïðèåì àñêîðáèíîâîé êèñëîòû (âèò. Ñ) äî 300-400 ìã â ñóòêè - òàáàêîêóðåíèå ïîíèæàåò åãî ñîäåðæàíèå â êðîâè).

áîëåå äîñòóïíîå çíàêîìñòâî ñ âàøèì çàáîëåâàíèåì - íà ñàéòå [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 16.06.2003, 14:49
BION22 BION22 âíå ôîðóìà
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 16.06.2003
Ãîðîä: ÈÇÐÀÈËÜ
Ñîîáùåíèé: 20
BION22 ýòîò ó÷àñòíèê èìååò îòâðàòèòåëüíóþ ðåïóòàöèþ íà ôîðóìå
ÓÂ.ÅËÅÍÀ.
ß ÁÛ ÏÎÑÎÂÅÒÎÂÀË ÂÀÌ ÎÁÐÀÒÈÒÑß Ê ÑÏÅÖÈÀËÈÑÒÓ ÏÐÀÊÒÈÊÓÞÙÅÌÓ ÀÊÊÓÏÓÍÊÒÓÐÓ ÑÓ ÄÆÎÊ È ÏÐÎÈÒÈ ÊÓÐÑ ÌÀÃÍÈÒÎÒÅÐÀÏÈÈ. Ó ÂÀÑ ÈÇÁÛÒÎÊ ÝÍÅÐÃÈÈ Â ÌÅÐÈÄÈÀÍÅ ÏÎ×ÅÊ ,×ÒÎ ×ÀÑÒÎ ÂÛÇÛÂÀÅÒ ÃÎËÎÂÍÛÅ ÁÎËÈ
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 16.06.2003, 22:26
Gromoboy Gromoboy âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
 
Ðåãèñòðàöèÿ: 29.05.2003
Ñîîáùåíèé: 237
Gromoboy
Äà óæ, äèêëîôåíàê òóò ñîâñåì êñòàòè...
Ëåíà, îïèøèòå ïîæàëóéñòà. êàê íà÷èíàþòñÿ ãîëîâíûå áîëè - îò çàòûëêà êî ëáó èëè íàîáîðîò - îò ëáà ê çàòûëêó? Êàêàÿ ñòîðîíà ñòðàäàåò - ëåâàÿ èëè ïðàâàÿ? Êîãäà è îò ÷åãî óëó÷øåíèå/óõóäøåíèå ( åäà, âðåìÿ ñóòîê è ïð.)? Óñèëèâàåòñÿ-ëè áîëü êîãäà Âû çàïðîêèäûâàåòå ãîëîâó íàçàä? Èëè êîãäà íàêëîíÿåòå åå âíèç? Åñòü-ëè ñâÿçü áîëåé ñ ìåíñòðóàöèÿìè è êàêîâ èõ õàðàêòåð? áûëè-ëè òðàâìû ãîëîâû èëè íåéðîèíôåêöèè (ìåíèíòèò. ýíöåôàëèò)?
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 17.06.2003, 10:43
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,505
Ïîáëàãîäàðèëè 33,289 ðàç(à) çà 31,637 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Gromoboy!
Íå âèæó ïðè÷èí äëÿ ñêåïñèñà, äëÿ áîëüøåé îñâåäîìëåííîñòè çàãëÿíèòå ê êëàññèêàì:

Cephalalgia. 1999 May;19(4):232-40.
Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
BACKGROUND: Migraine attacks are often treated with simple analgesics or with ergotamine-containing preparations alone or in combination with anti-emetics. Although also sometimes used to treat migraine, nonsteroidal anti-inflammatory drugs (NSAIDs) have not been systematically evaluated in controlled clinical trials, particularly in comparison with the newer drug sumatriptan. Sumatriptan is a specific migraine treatment which has recently become among the most widely prescribed acute migraine therapies. However, while effective, it has low oral bioavailability and some problematic adverse effects. Diclofenac-potassium is a potent NSAID available as a fast-acting oral tablet, which has been shown to be safe and effective in several other acute pain indications. In the clinical trial reported here, the efficacy and safety of diclofenac-potassium in the acute treatment of migraine attacks has been tested in comparison with oral sumatriptan and placebo. METHODS: Single oral doses of 50 mg and 100 mg diclofenac-potassium were compared to a single oral dose of 100 mg sumatriptan and placebo in a double-blind randomized crossover trial in 156 adult patients suffering from migraine attacks, with or without aura, selected according to the International Headache Society diagnostic criteria. The primary efficacy criterion was migraine headache pain recorded on a visual analog scale at 2 h after dosing. Secondary endpoints included pain at other time points up to 8 h and the presence of accompanying symptoms (nausea, vomiting, photophobia, phonophobia). FINDINGS: Diclofenac-potassium was more effective than placebo in reducing migraine headache pain at 2 h after dosing, which was the primary endpoint. Secondary analyses showed that diclofenac-potassium provided significant pain relief from 60 min after dosing and for all remaining endpoints in the 8-h observation period. Both 50 and 100 mg doses of diclofenac-potassium were similarly effective. A similar effect was shown with sumatriptan; however, significant superiority to placebo was seen only from the 90-min time point. Diclofenac-potassium was generally superior to placebo or sumatriptan in reducing accompanying symptoms, particularly nausea. Diclofenac-potassium seemed to be as well tolerated as placebo, with fewer adverse events reported than after sumatriptan treatment and with more patients assessing the overall tolerability of diclofenac-potassium better than that of sumatriptan. INTERPRETATION: Compared with placebo and the reference therapy sumatriptan, diclofenac-potassium is an effective, fast-acting, and well-tolerated acute oral therapy for migraine attacks, with advantages over oral sumatriptan in terms of onset of analgesic effect, reduction of accompanying symptoms, and tolerability profile. It may therefore be useful as an alternative oral therapy for migraine attacks.

Drugs. 1999 Jun;57(6):991-1003.
Diclofenac-potassium in migraine: a review.
McNeely W, Goa KL.
Adis International Limited, Auckland, Mairangi Bay, New Zealand.
The NSAID diclofenac is a potent inhibitor of prostaglandin synthesis and an established antipyretic and analgesic agent. Diclofenac-potassium was developed as an immediate-release tablet with the aim of providing rapid onset of action after oral administration. This formulation has been investigated in the acute treatment of migraine. Data from available placebo-controlled clinical trials indicate that diclofenac-potassium 50 or 100mg as an immediate-release tablet is more effective than placebo and as effective as oral sumatriptan 100mg and ergotamine plus caffeine at reducing pain intensity in patients with migraine 2 hours after initial administration. Duration of pain relief is similar for the 3 drugs but onset appears to be faster with diclofenac-potassium than with oral sumatriptan or ergotamine plus caffeine. Diclofenac-potassium appears to have favourable effects on some accompanying symptoms such as nausea and vomiting. The frequency of these symptoms was significantly lower with diclofenac-potassium than with sumatriptan in 1 study, although only a few patients had vomiting at baseline. Effects on phonophobia or photophobia did not differ between diclofenac-potassium, sumatriptan and ergotamine plus caffeine. The need for rescue medication is consistently less with diclofenac-potassium than with placebo. Data are inconsistent or scarce regarding the effects of diclofenac-potassium versus placebo on other measures such as headache recurrence and working ability. Diclofenac-potassium was generally well tolerated in clinical trials in patients with migraine. Adverse events reported most frequently (abdominal pain, tiredness and fatigue and nausea) were typically mild to moderate. CONCLUSION: Diclofenac-potassium provides rapid pain relief (within 60 to 90 minutes), is well tolerated and reduces the frequency of some of the accompanying symptoms in patients with migraine. Available trials indicate that diclofenac-potassium provides similar pain relief to sumatriptan and is at least as effective as ergotamine plus caffeine, but appears to have a greater effect on nausea and vomiting than sumatriptan and a faster onset of action than both drugs. Comparisons with other NSAIDs are lacking. Diclofenac-potassium is likely to find a role as a useful first-line option in the acute treatment of migraine.
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 17.06.2003, 20:57
Gromoboy Gromoboy âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
 
Ðåãèñòðàöèÿ: 29.05.2003
Ñîîáùåíèé: 237
Gromoboy
Î-êåé, ïðî÷èòàë. Íî êàêîâû ïîñëåäñòâèÿ ïîñòîÿííîãî ïðèåìà äèêëîôåíàêà? Ïðåïàðàò âåñüìà òîêñè÷åí. Íå ñïîðþ. ìîæíî íàéòè ðÿä ñòàòåé. ãäå ÷åðíûì ïî áåëîìó äîêàçûâàåòñÿ, ÷òî åãî òîêñè÷íîñòü íèæå, ÷åì ó àíàëîãîâ. îäíàêî "íàçíà÷àåì ïî òåîðèè, ïîëó÷àåì ïî ïðàêòèêå". Íà îñíîâàíèè ñâîåãî îïûòà ÿ ñäåëàë âûâîä î ÍÅÄÎÏÓÑÒÈÌÎÑÒÈ äëèòåëüíîãî ïðèìåíåèíÿ äèêëîôåíàêà (à ðàâíî è äèêëîâèòà) â ìåäèöèíñêîé ïðàêòèêå.
Íå íàñòàèâàþ íà òîì, ÷òî ýòî èñòèíà â ïîñëåäíåé èíñòàíöèè, íî ïîïàäàþùèõ â ìîè ðóêè áîëüíûõ ïîëó÷àþùèõ äèêëîôåíàê, ÿ ïîñòåïåííî "ñíèìàþ" ñ ýòîãî ïðåïàðàòà. Êàê ïðàâèëî. óñïåøíî è. ÷òî ñàìîå èíòåðåñíîå, ýòè æå áîëüíûå â äàëüíåéøåì ïðåêðàñíî áåç íåãî îáõîäÿòñÿ.  ñèëó ÷åãî âîçíèêàåò âîïðîñ - à íàñêîëüêî âîîáùå áûëî îïðàâäàíî èñõîäíîå íàçíà÷åíèå äèêëîôåíàêà?
Îòâåòèòü ñ öèòèðîâàíèåì
  #8  
Ñòàðûé 06.08.2003, 14:40
EIsaguljan EIsaguljan âíå ôîðóìà
Ñåðôåð
 
Ðåãèñòðàöèÿ: 24.11.2002
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 4
EIsaguljan *
Exclamation

Óâàæàåìàÿ Åëåíà! Åñëè Âû èñïðîáîâàëè ìíîæåñòâî ëåêàðñòâåííûõ ñðåäñòâ ( âòîì ÷èñëå ñïåöèôè÷åñêèå àíòèìèãðåíîçíûå ñðåäñòâà, òàêèå êàê ñóìàòðèïòàí), à òàêæå ðåôëåêñîòåðàïèþ áåç îïðåäåëåííîãî ýôôåêòà, áåçóñëîâíî ìîæíî ïîðåêîìåíäîâàòü Âàì ëå÷åíèå ñ ïîìîùüþ âûñîêèõ òåõíîëîãèé â íåâðîëîãèè - ìåòîäîì íåéðîìîäóëÿöèè.
Ìåòîä íåéðîìîäóëÿöè ïðèøåë ê íàì èç-çà ðóáåæà. Âûñîêàÿ ðåçóëüòàòèâíîñòü ñäåëàëà åãî ïîïóëÿðíûì â êëèíèêàõ Åâðîïû, ÑØÀ, Êàíàäû, ßïîíèè. Òåïåðü îí ñòàë ïðèìåíÿòüñÿ è â Ðîññèè, ïðàâäà, ïîêà òîëüêî â ÍÈÈ ÍÕ èì. Áóðäåíêî.
Äëÿ Ðîññèéñêîé Ôåäåðàöèè ìåòîäû íåéðîìîäóëÿöèè â ëå÷åíèè õðîíè÷åñêèõ áîëåâûõ ñèíäðîìîâ ÿâëÿþòñÿ íîâûìè.
Íåéðîìîäóëÿöèÿ - ìàëîèíâàçèâíûå ìåòîäû îïåðàòèâíûõ âìåøàòåëüñòâ, ñâÿçàííûå ñ ýëåêòðè÷åñêîé è ìåäèàòîðíîé ñòèìóëÿöèåé ðàçëè÷íûõ îòäåëîâ íåðâíîé ñèñòåìû. Äàííûé ìåòîä íå ÿâëÿåòñÿ àëüòåðíàòèâíûì èëè íåòðàäèöèîííûì. Ýòî ìåòîä ôóíêöèîíàëüíîé íåéðîõèðóðãèè, êîòîðûé óæå áîëåå 20-òè ëåò óñïåøíî ïðèìåíÿåòñÿ â ðàçâèòûõ ñòðàíàõ ìèðà. Èñïîëüçóÿ õðîíè÷åñêóþ ýëåêòðîñòèìóëÿöèþ, ìîæíî ïîëó÷àòü æåëàåìûå êëèíè÷åñêèå ýôôåêòû íå ðàçðóøàÿ òêàíè. Èìïëàíòèðóåìûé ãåíåðàòîð èëè ïðèåìíèê ÷åðåç ýëåêòðîä îêàçûâàþò èìïóëüñíîå âîçäåéñòâèå íà
çàðàíåå âûáðàííûå ñòðóêòóðû íåðâíîé ñèñòåìû. Íàïðèìåð, â âàøåì ñëó÷àå, òîíêèé (äèàìåòðîì ñ òîíêóþ áóëàâêó) ýëåêòðîä óñòàíàâëèâàåòñÿ â íàèáîëåå áîëåçíåííîé, òðèããåðíîé òî÷êå(òî÷êå, ñ êîòîðîé îáû÷íî íà÷èíàåòñÿ âàøà ãîëîâíàÿ áîëü) - îáû÷íî â âèñî÷íîé îáëàñòè, â íåïîñðåäñòâåííîé áëèçîñòè ñ íåðâíûì ñèìïàòè÷åñêèì ïåðèàðòåðèàëüíûì ñïëåòåíèåì) è ïîäñîåäèíÿåòñÿ ñ ãåíåðàòîðîì èìïóëüñîâ (ðàçìåðîì ñ 5-ðóáëåâóþ ìîíåòó) êîòîðûé ïåðåäàåò ê êîíòàêòó ýëåêòðîäà èìïóëüñû ïîäàâëÿþùèå áîëü. Õàðàêòåðèñòèêè èìïóëüñà(÷àñòîòà, àìïëèòóäà äëèòåëüíîñòü) çàðàíåå ïðîãðàììèðóþòñÿ âðà÷îì ñ ïîìîùüþ âðà÷åáíîãî ïðîãðàììàòîðà. Ñàìà ñèñòåìà íåçàìåòíà íè îêðóæàþùèì íè äàæå âàì. Ýëåêòðîä è ãåíåðàòîð íàõîäÿòñÿ ïîä êîæåé. Ïîñëåäíèé îáû÷íî ðàçìåùàåòñÿ â ïîäêëþ÷è÷íîé îáëàñòè.
Îñíîâíûì ïðåèìóùåñòâîì äàííîãî ìåòîäà ëå÷åíèÿ ÿâëÿåòñÿ - "óïðàâëåíèå áîëüþ" - Âû ñàìè âêëþ÷àåòå ñòèìóëÿòîð êîãäà ýòî íåîáõîäèìî (íà 5-10 ìèí.) è ïîäàâëÿåòå áîëü ïðàêòè÷åñêè ñðàçó è íàäîëãî. Âàì áîëüøå íå íóæíî áóäåò æäàòü êîãäà ïîìîæåò ëåêàðñòâî è ïîìîæåò ëè âîîáùå. Âû âîîáùå ìîæåòå îòêàçàòüñÿ îò êàêèõ - ëèáî ëåêàðñòâ èëè ÁÀÄ-îâ. Ïðîñòî - íàæìè íà êíîïêó íà ïðîãðàììàòîðå ïàöèåíòà (êîòîðûé ïðèêëàäûâàåòñÿ ê êîæå íàä ãåíåðàòîðîì èìïóëüñîâ) è ìîæåøü çàáûòü î áîëè. Êàæåòñÿ ôàíòàñòèêîé, íî ñåãîäíÿ ýòî óæå ÐÅÀËÜÍÎÑÒÜ!

Ñïèñîê îñíîâíûõ áîëåâûõ ñèíäðîìîâ, êîòîðûå óñïåøíî ëå÷àòñÿ ìåòîäàìè íåéðîìîäóëÿöèè:

1. à) Áîëü â êîíå÷íîñòÿõ - áîëåâûå ñèíäðîìû âñëåäñòâèå ïîâðåæäåíèÿ ïåðèôåðè÷åñêèõ íåðâîâ è ñïëåòåíèé (òðàâìàòè÷åñêîãî, âîñïàëèòåëüíîãî è èíîãî ïðîèñõîæäåíèÿ).  òîì ÷èñëå ÔÀÍÒÎÌÍÛÅ È ÊÓËÜÒÅÂÛÅ ÁÎËÈ.
á) Áîëü â êîíå÷íîñòÿõ ñâÿçàííàÿ ñî ñïàçìîì ñîñóäîâ (áîëåçíü Ðåéíî, îáëèòåðèðóþùèé ýíäàðòåðèèò è äð. àíãèîñïàñòè÷åñêèå ñîñòîÿíèÿ).  òàêèõ ñëó÷àÿõ ÝÑ îêàçûâàåò íå òîëüêî ïðîòèâîáîëåâîé ýôôåêò, íî è âîçäåéñòâóåò íà ñàìó ïðè÷èíó áîëè, óñòðàíÿÿ ñîñóäèñòûé ñïàçì.
2. Áîëü â ñïèíå - áîëåâûå ñèíäðîìû âñëåäñòâèå ïîâðåæäåíèÿ ñïèííîãî ìîçãà è åãî êîðåøêîâ (òðàâìàòè÷åñêîãî, âîñïàëèòåëüíîãî è èíîãî ïðîèñõîæäåíèÿ). Ñðåäè íèõ íàèáîëåå ðàñïðîñòðàíåííàÿ ãðóïïà ïàöèåíòîâ ñ òàê íàçûâàåìûì ñèíäðîìîì íåóäà÷íûõ îïåðàòèâíûõ âìåøàòåëüñòâ íà ïîçâîíî÷íèêå (FBSS - Failed Back Surgery Syndrom), êîòîðûé î÷åíü íåïëîõî ïîääàåòñÿ èìåííî ÝÑÍÑ, â ÷àñòíîñòè ýïèäóðàëüíîé ñòèìóëÿöèè ñïèííîãî ìîçãà. Ôàñåòî÷íûé áîëåâîé ñèíäðîì, ìèîôàñöèàëüíûé áîëåâîé ñèíäðîì è äðóãèå âåðòåáðîãåííûå (ñâÿçàííûå ñ ïàòîëîãèåé ïîçâîíî÷íèêà) áîëè, íå ïîääàþùèåñÿ êîíñåðâàòèâíîé òåðàïèè è íå èìåþùèå ïðÿìûõ ïîêàçàíèé ê õèðóðãè÷åñêîìó ëå÷åíèþ ïî ïîâîäó îñíîâíîãî çàáîëåâàíèÿ (íàïðèìåð, ãðûæà ì/ï äèñêà).
3. Áîëü â ãðóäíîé êëåòêå - ìåæðåáåðíàÿ íåâðàëãèÿ è ïîñòòîðàêîòîìè÷åñêèé (ïîñëå îïåðàöèé ñî âñêðûòèåì ãðóäíîé êëåòêè) áîëåâîé ñèíäðîì.  òîì ÷èñëå êàðäèàëüíûå áîëè – áîëü ïðè ñòåíîêàðäèè. Ïðè òàêîé áîëè îïåðàöèÿ ïî èìïëàíòàöèè ñèñòåìû äëÿ õðîíè÷åñêîé ñòèìóëÿöèè óñòðàíÿåò íå òîëüêî áîëü, íî è åå ïðè÷èíó – ñïàçì êîðîíàðíûõ ñîñóäîâ è ñîîòâåòñòâåííî èøåìèþ, ÷àñòî ÿâëÿÿñü àëüòåðíàòèâîé øóíòèðóþùèì îïåðàöèÿì.
4. Ãîëîâíàÿ áîëü – áîëåâûå ñèíäðîìû âñëåäñòâèå ïîâðåæäåíèÿ ÷åðåïíî-ìîçãîâûõ íåðâîâ (òðàâìàòè÷åñêîãî, âîñïàëèòåëüíîãî è èíîãî ïðîèñõîæäåíèÿ).  íîâîñòÿõ íà íàøåì ñàéòå âû ìîæåòå òàêæå îçíàêîìèòüñÿ ñ ïåðâûì îïûòîì ëå÷åíèÿ ÌÈÃÐÅÍÈ ìåòîäîì íåéðîìîäóëÿöèè.
5. Íåâðàëãèÿ òðîéíè÷íîãî íåðâà è äð. ëèöåâûå áîëè.
6. Ïîñëåäñòâèÿ òðàâì, íàðóøåíèé êðîâîîáðàùåíèÿ, íåéðîèíôåêöèè è äð.:
à) áîëåâûå ñèíäðîìû âñëåäñòâèå íàðóøåíèé ìîçãîâîãî êðîâîîáðàùåíèÿ (òàëàìè÷åñêèå áîëè).
á) áîëåâûå ñèíäðîìû âñëåäñòâèå îíêîëîãè÷åñêèõ ïðîöåññîâ.
7. Êîìïëåêñíûé ðåãèîíàðíûé áîëåâîé ñèíäðîì – ÊÐÁÑ (êàóçàëãèÿ).

Äëÿ áîëåå äåòàëüíîé èíôîðìàöèè çàãëÿíèòå íà íàø ñàéò - [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
ß òàêæå îòâå÷ó íà Âàøå ïèñüìî.

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
  #9  
Ñòàðûé 06.08.2003, 14:50
EIsaguljan EIsaguljan âíå ôîðóìà
Ñåðôåð
 
Ðåãèñòðàöèÿ: 24.11.2002
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 4
EIsaguljan *
Exclamation

Óâàæàåìàÿ Åëåíà! Åñëè Âû èñïðîáîâàëè ìíîæåñòâî ëåêàðñòâåííûõ ñðåäñòâ ( âòîì ÷èñëå ñïåöèôè÷åñêèå àíòèìèãðåíîçíûå ñðåäñòâà, òàêèå êàê ñóìàòðèïòàí), à òàêæå ðåôëåêñîòåðàïèþ áåç îïðåäåëåííîãî ýôôåêòà, áåçóñëîâíî ìîæíî ïîðåêîìåíäîâàòü Âàì ëå÷åíèå ñ ïîìîùüþ âûñîêèõ òåõíîëîãèé â íåâðîëîãèè - ìåòîäîì íåéðîìîäóëÿöèè.
Ìåòîä íåéðîìîäóëÿöè ïðèøåë ê íàì èç-çà ðóáåæà. Âûñîêàÿ ðåçóëüòàòèâíîñòü ñäåëàëà åãî ïîïóëÿðíûì â êëèíèêàõ Åâðîïû, ÑØÀ, Êàíàäû, ßïîíèè. Òåïåðü îí ñòàë ïðèìåíÿòüñÿ è â Ðîññèè, ïðàâäà, ïîêà òîëüêî â ÍÈÈ ÍÕ èì. Áóðäåíêî.
Äëÿ Ðîññèéñêîé Ôåäåðàöèè ìåòîäû íåéðîìîäóëÿöèè â ëå÷åíèè õðîíè÷åñêèõ áîëåâûõ ñèíäðîìîâ ÿâëÿþòñÿ íîâûìè.
Íåéðîìîäóëÿöèÿ - ìàëîèíâàçèâíûå ìåòîäû îïåðàòèâíûõ âìåøàòåëüñòâ, ñâÿçàííûå ñ ýëåêòðè÷åñêîé è ìåäèàòîðíîé ñòèìóëÿöèåé ðàçëè÷íûõ îòäåëîâ íåðâíîé ñèñòåìû. Äàííûé ìåòîä íå ÿâëÿåòñÿ àëüòåðíàòèâíûì èëè íåòðàäèöèîííûì. Ýòî ìåòîä ôóíêöèîíàëüíîé íåéðîõèðóðãèè, êîòîðûé óæå áîëåå 20-òè ëåò óñïåøíî ïðèìåíÿåòñÿ â ðàçâèòûõ ñòðàíàõ ìèðà. Èñïîëüçóÿ õðîíè÷åñêóþ ýëåêòðîñòèìóëÿöèþ, ìîæíî ïîëó÷àòü æåëàåìûå êëèíè÷åñêèå ýôôåêòû íå ðàçðóøàÿ òêàíè. Èìïëàíòèðóåìûé ãåíåðàòîð èëè ïðèåìíèê ÷åðåç ýëåêòðîä îêàçûâàþò èìïóëüñíîå âîçäåéñòâèå íà
çàðàíåå âûáðàííûå ñòðóêòóðû íåðâíîé ñèñòåìû. Íàïðèìåð, â âàøåì ñëó÷àå, òîíêèé (äèàìåòðîì ñ òîíêóþ áóëàâêó) ýëåêòðîä óñòàíàâëèâàåòñÿ â íàèáîëåå áîëåçíåííîé, òðèããåðíîé òî÷êå(òî÷êå, ñ êîòîðîé îáû÷íî íà÷èíàåòñÿ âàøà ãîëîâíàÿ áîëü) - îáû÷íî â âèñî÷íîé îáëàñòè, â íåïîñðåäñòâåííîé áëèçîñòè ñ íåðâíûì ñèìïàòè÷åñêèì ïåðèàðòåðèàëüíûì ñïëåòåíèåì) è ïîäñîåäèíÿåòñÿ ñ ãåíåðàòîðîì èìïóëüñîâ (ðàçìåðîì ñ 5-ðóáëåâóþ ìîíåòó) êîòîðûé ïåðåäàåò ê êîíòàêòó ýëåêòðîäà èìïóëüñû ïîäàâëÿþùèå áîëü. Õàðàêòåðèñòèêè èìïóëüñà(÷àñòîòà, àìïëèòóäà äëèòåëüíîñòü) çàðàíåå ïðîãðàììèðóþòñÿ âðà÷îì ñ ïîìîùüþ âðà÷åáíîãî ïðîãðàììàòîðà. Ñàìà ñèñòåìà íåçàìåòíà íè îêðóæàþùèì íè äàæå âàì. Ýëåêòðîä è ãåíåðàòîð íàõîäÿòñÿ ïîä êîæåé. Ïîñëåäíèé îáû÷íî ðàçìåùàåòñÿ â ïîäêëþ÷è÷íîé îáëàñòè.
Îñíîâíûì ïðåèìóùåñòâîì äàííîãî ìåòîäà ëå÷åíèÿ ÿâëÿåòñÿ - "óïðàâëåíèå áîëüþ" - Âû ñàìè âêëþ÷àåòå ñòèìóëÿòîð êîãäà ýòî íåîáõîäèìî (íà 5-10 ìèí.) è ïîäàâëÿåòå áîëü ïðàêòè÷åñêè ñðàçó è íàäîëãî. Âàì áîëüøå íå íóæíî áóäåò æäàòü êîãäà ïîìîæåò ëåêàðñòâî è ïîìîæåò ëè âîîáùå. Âû âîîáùå ìîæåòå îòêàçàòüñÿ îò êàêèõ - ëèáî ëåêàðñòâ èëè ÁÀÄ-îâ. Ïðîñòî - íàæìè íà êíîïêó íà ïðîãðàììàòîðå ïàöèåíòà (êîòîðûé ïðèêëàäûâàåòñÿ ê êîæå íàä ãåíåðàòîðîì èìïóëüñîâ) è ìîæåøü çàáûòü î áîëè. Êàæåòñÿ ôàíòàñòèêîé, íî ñåãîäíÿ ýòî óæå ÐÅÀËÜÍÎÑÒÜ!

Ñïèñîê îñíîâíûõ áîëåâûõ ñèíäðîìîâ, êîòîðûå óñïåøíî ëå÷àòñÿ ìåòîäàìè íåéðîìîäóëÿöèè:

1. à) Áîëü â êîíå÷íîñòÿõ - áîëåâûå ñèíäðîìû âñëåäñòâèå ïîâðåæäåíèÿ ïåðèôåðè÷åñêèõ íåðâîâ è ñïëåòåíèé (òðàâìàòè÷åñêîãî, âîñïàëèòåëüíîãî è èíîãî ïðîèñõîæäåíèÿ).  òîì ÷èñëå ÔÀÍÒÎÌÍÛÅ È ÊÓËÜÒÅÂÛÅ ÁÎËÈ.
á) Áîëü â êîíå÷íîñòÿõ ñâÿçàííàÿ ñî ñïàçìîì ñîñóäîâ (áîëåçíü Ðåéíî, îáëèòåðèðóþùèé ýíäàðòåðèèò è äð. àíãèîñïàñòè÷åñêèå ñîñòîÿíèÿ).  òàêèõ ñëó÷àÿõ ÝÑ îêàçûâàåò íå òîëüêî ïðîòèâîáîëåâîé ýôôåêò, íî è âîçäåéñòâóåò íà ñàìó ïðè÷èíó áîëè, óñòðàíÿÿ ñîñóäèñòûé ñïàçì.
2. Áîëü â ñïèíå - áîëåâûå ñèíäðîìû âñëåäñòâèå ïîâðåæäåíèÿ ñïèííîãî ìîçãà è åãî êîðåøêîâ (òðàâìàòè÷åñêîãî, âîñïàëèòåëüíîãî è èíîãî ïðîèñõîæäåíèÿ). Ñðåäè íèõ íàèáîëåå ðàñïðîñòðàíåííàÿ ãðóïïà ïàöèåíòîâ ñ òàê íàçûâàåìûì ñèíäðîìîì íåóäà÷íûõ îïåðàòèâíûõ âìåøàòåëüñòâ íà ïîçâîíî÷íèêå (FBSS - Failed Back Surgery Syndrom), êîòîðûé î÷åíü íåïëîõî ïîääàåòñÿ èìåííî ÝÑÍÑ, â ÷àñòíîñòè ýïèäóðàëüíîé ñòèìóëÿöèè ñïèííîãî ìîçãà. Ôàñåòî÷íûé áîëåâîé ñèíäðîì, ìèîôàñöèàëüíûé áîëåâîé ñèíäðîì è äðóãèå âåðòåáðîãåííûå (ñâÿçàííûå ñ ïàòîëîãèåé ïîçâîíî÷íèêà) áîëè, íå ïîääàþùèåñÿ êîíñåðâàòèâíîé òåðàïèè è íå èìåþùèå ïðÿìûõ ïîêàçàíèé ê õèðóðãè÷åñêîìó ëå÷åíèþ ïî ïîâîäó îñíîâíîãî çàáîëåâàíèÿ (íàïðèìåð, ãðûæà ì/ï äèñêà).
3. Áîëü â ãðóäíîé êëåòêå - ìåæðåáåðíàÿ íåâðàëãèÿ è ïîñòòîðàêîòîìè÷åñêèé (ïîñëå îïåðàöèé ñî âñêðûòèåì ãðóäíîé êëåòêè) áîëåâîé ñèíäðîì.  òîì ÷èñëå êàðäèàëüíûå áîëè – áîëü ïðè ñòåíîêàðäèè. Ïðè òàêîé áîëè îïåðàöèÿ ïî èìïëàíòàöèè ñèñòåìû äëÿ õðîíè÷åñêîé ñòèìóëÿöèè óñòðàíÿåò íå òîëüêî áîëü, íî è åå ïðè÷èíó – ñïàçì êîðîíàðíûõ ñîñóäîâ è ñîîòâåòñòâåííî èøåìèþ, ÷àñòî ÿâëÿÿñü àëüòåðíàòèâîé øóíòèðóþùèì îïåðàöèÿì.
4. Ãîëîâíàÿ áîëü – áîëåâûå ñèíäðîìû âñëåäñòâèå ïîâðåæäåíèÿ ÷åðåïíî-ìîçãîâûõ íåðâîâ (òðàâìàòè÷åñêîãî, âîñïàëèòåëüíîãî è èíîãî ïðîèñõîæäåíèÿ).  íîâîñòÿõ íà íàøåì ñàéòå âû ìîæåòå òàêæå îçíàêîìèòüñÿ ñ ïåðâûì îïûòîì ëå÷åíèÿ ÌÈÃÐÅÍÈ ìåòîäîì íåéðîìîäóëÿöèè.
5. Íåâðàëãèÿ òðîéíè÷íîãî íåðâà è äð. ëèöåâûå áîëè.
6. Ïîñëåäñòâèÿ òðàâì, íàðóøåíèé êðîâîîáðàùåíèÿ, íåéðîèíôåêöèè è äð.:
à) áîëåâûå ñèíäðîìû âñëåäñòâèå íàðóøåíèé ìîçãîâîãî êðîâîîáðàùåíèÿ (òàëàìè÷åñêèå áîëè).
á) áîëåâûå ñèíäðîìû âñëåäñòâèå îíêîëîãè÷åñêèõ ïðîöåññîâ.
7. Êîìïëåêñíûé ðåãèîíàðíûé áîëåâîé ñèíäðîì – ÊÐÁÑ (êàóçàëãèÿ).

Äëÿ áîëåå äåòàëüíîé èíôîðìàöèè çàãëÿíèòå íà íàø ñàéò - [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
ß òàêæå îòâå÷ó íà Âàøå ïèñüìî.

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 17:22.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.